Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study.

@article{Vachiry2017AmbrisentanUF,
  title={Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study.},
  author={J-L. Vachi{\'e}ry and Marius M Hoeper and AndrewJ. Peacock and Olivier Sitbon and Martino Cheli and Colin C Church and Karen M. Olsson and Massimiliano Palazzini and Brian R Waterhouse and Jonathan Langley and Nazzereno Gali{\`e}},
  journal={The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation},
  year={2017},
  volume={36 4},
  pages={
          399-406
        }
}
BACKGROUND The VOLibris Tracking (VOLT) Study was an open-label, prospective, observational, multicenter, post-marketing registry program designed to more fully characterize the safety profile of ambrisentan for the treatment of pulmonary arterial hypertension (PAH). The key outcome was the incidence of aminotransferase elevations >3× the upper limit of normal (ULN). METHODS In total, 999 patients from 115 centers in 15 countries, who were prescribed ambrisentan for the treatment of PAH… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 10 times. VIEW TWEETS